| Vitura Health Limited (VIT) ORDINARY FULLY PAID |
Health Care |
$47 |
Investor webinar and presentation
|
28 Feb 2025 10:01AM |
$0.078 |
$0.071 |
fallen by
8.97%
|
|
| QBE Insurance Group Limited (QBE) ORDINARY FULLY PAID |
Financials |
$32,435 |
Application for quotation of securities - QBE
|
28 Feb 2025 10:01AM |
$21.710 |
$21.480 |
fallen by
1.06%
|
|
| Australian Bond Exchange Holdings Limited (ABE) ORDINARY FULLY PAID |
Financials |
$4 |
Half Yearly Report and Accounts
|
28 Feb 2025 10:01AM |
$0.029 |
$0.035 |
risen by
20.69%
|
|
ABE - Price-sensitive ASX Announcement
Full Release
Key Points
- Consolidated loss of $1,920,086 for the half-year.
- Loss reduction attributed to cost optimization measures.
- Total cost base reduced significantly by 42%.
- Company focused on growth and product innovations.
- Introduced new market-linked securities to the Australian market.
- No dividends declared or paid during the financial year.
- Net assets at 31 December 2024 were $784,129.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$194 |
Half Yearly Report and Accounts
|
28 Feb 2025 10:00AM |
$0.038 |
$0.026 |
fallen by
31.58%
|
|
IMU - Price-sensitive ASX Announcement
Full Release
Key Points
- Reported net loss of $48,338,627 for the half year ended 31 December 2024.
- Loss reduced from $68,714,834 compared to the previous year.
- Decreased clinical trial costs contributed to reduced losses.
- Secured $20 million from convertible notes to fund ongoing clinical trials.
- Received $11.7 million R&D tax incentive refund.
- Positive results reported in azer-cel CAR T-cell therapy trial.
- First patient enrolled in azer-cel Phase 1b trial in Australia.
- onCARlytics trial progresses with the first patient dosed.
- VAXINIA received Orphan Drug Designation for biliary tract cancer.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Elixinol Wellness Limited (EXL) ORDINARY FULLY PAID |
Consumer Staple |
$5 |
FY24 Appendix 4E and Annual Report
|
28 Feb 2025 10:00AM |
$0.032 |
$0.022 |
fallen by
31.25%
|
|
EXL - Price-sensitive ASX Announcement
Full Release
Key Points
- FY24 revenue reached $15.0 million, up 80.9% from FY23.
- Loss after tax decreased to $1.722 million, down 77.1% from the previous year.
- Successful acquisitions include The Healthy Chef and Ananda Food, enhancing revenue streams.
- Elixinol Americas transitioned to an e-commerce model, contributing positively to EBITDA.
- The company aims to strengthen operational foundations and product pipeline for FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$577 |
Cleansing Notice - Capital Call
|
28 Feb 2025 9:59AM |
$0.258 |
$0.285 |
risen by
10.68%
|
|
| First Graphene Limited (FGR) ORDINARY FULLY PAID |
Materials |
$30 |
Prospesctus - Listed Options
|
28 Feb 2025 9:59AM |
$0.041 |
$0.040 |
fallen by
2.44%
|
|
FGR - Price-sensitive ASX Announcement
Full Release
Key Points
- Prospectus issued for a pro-rata non-renounceable entitlement issue.
- Approximately 186,932,376 New Options to be offered at $0.005 each.
- Goal to raise up to $934,662 from the entitlement offer.
- Eligible shareholders can receive one New Option for every four Shares held.
- Options will expire on 30 June 2027 with an exercise price of 8.5 cents.
- 6,000,000 Broker Options will be granted to selected brokers.
- Funds raised will be used for commercial opportunities and working capital.
- Investment in New Options considered highly speculative.
- Prospectus emphasizes that no cooling-off rights apply to investments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$577 |
Cleansing Notice - Trust
|
28 Feb 2025 9:59AM |
$0.258 |
$0.285 |
risen by
10.68%
|
|
| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$577 |
Application for quotation of securities - BRN
|
28 Feb 2025 9:57AM |
$0.258 |
$0.285 |
risen by
10.68%
|
|
| Acorn Capital Investment Fund Limited (ACQ) ORDINARY FULLY PAID |
Financials |
$66 |
Update - Dividend/Distribution - ACQ
|
28 Feb 2025 9:56AM |
$0.800 |
$0.740 |
fallen by
7.50%
|
|
| Careteq Limited (CTQ) ORDINARY FULLY PAID |
Health Care |
$3 |
1HFY25 Results Presentation
|
28 Feb 2025 9:55AM |
$0.014 |
$0.012 |
fallen by
14.29%
|
|
| Kina Securities Limited (KSL) ORDINARY FULLY PAID |
Financials |
$315 |
FY24 Results Investor Presentation
|
28 Feb 2025 9:55AM |
$1.170 |
$1.090 |
fallen by
6.84%
|
|
KSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Loan book growth of 13% driven by strong business lending.
- Foreign exchange revenues increased by 68% due to customer inflows.
- Digital channels and partnerships saw a 27% year-on-year growth.
- Underlying NPAT increased by 7%, with net profit before tax up 5%.
- The company maintained a dividend per share of 10.0 cents.
- Capital adequacy remains healthy, supporting growth opportunities.
- Kina Securities recognized for innovation in the Pacific banking sector.
- Community programs supported 14 small-scale projects in Papua New Guinea.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aeris Resources Limited (AIS) ORDINARY FULLY PAID |
Materials |
$174 |
INVESTOR PRESENTATION
|
28 Feb 2025 9:55AM |
$0.165 |
$0.180 |
risen by
9.09%
|
|
AIS - Price-sensitive ASX Announcement
Full Release
Key Points
- Aeris Resources Limited is an Australian mid-tier base and precious metals producer.
- The company has two producing operations with a FY25 production guidance of 40-48kt copper equivalent.
- It has three development projects poised for growth and exploration.
- Strategically located assets are aligned with a focus on copper production.
- Tritton is identified as a cornerstone asset with significant resource potential.
- Strong operating cash flow is funding further growth and development initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Careteq Limited (CTQ) ORDINARY FULLY PAID |
Health Care |
$3 |
1HFY25 Results Announcement
|
28 Feb 2025 9:55AM |
$0.014 |
$0.012 |
fallen by
14.29%
|
|
| The Star Entertainment Group Limited (SGR) ORDINARY FULLY PAID |
Consumer Discretionary |
$301 |
Pause in Trading
|
28 Feb 2025 9:54AM |
$0.130 |
$0.105 |
fallen by
19.23%
|
|
SGR - Price-sensitive ASX Announcement
Full Release
Key Points
- The Star Entertainment Group Limited has paused trading in its securities.
- The trading halt is pending a further announcement.
- The halt is in compliance with ASX Listings requirements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Careteq Limited (CTQ) ORDINARY FULLY PAID |
Health Care |
$3 |
1HFY25 Appendix 4D and Half Year Report
|
28 Feb 2025 9:54AM |
$0.014 |
$0.012 |
fallen by
14.29%
|
|
CTQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Careteq Limited divested its Sofihub business for $0.58 million.
- Acquired remaining 45% of Embedded Health Solutions for $2.4 million.
- Revenue increased by 15.5% to $4.0 million in 1H FY25.
- EBITDA from continuing operations improved to $0.24 million.
- Net loss reduced by 89.8% to $150,152.
- Partnerships with MedicAlert and GP networks to enhance medication safety.
- The company expects continued revenue growth and positive EBITDA for FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Holista Colltech Limited (HCT) ORDINARY FULLY PAID |
Consumer Staple |
$12 |
Appendix 4E - Preliminary Final Report
|
28 Feb 2025 9:53AM |
$0.030 |
$0.043 |
risen by
43.33%
|
|
HCT - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue declined 6% to $5.6 million.
- Net loss reduced by 98% to $84,000.
- Launched new products SKNPRO Collagen and PROBIO-30.
- Recovered $1 million from receivables.
- Secured forward orders worth $163,000 from Nano Malaysia.
- Ovine Collagen segment experienced a 50.7% sales decline but has potential new applications.
- Company is in discussions for a new manufacturing facility in collaboration with governments in Australia and Malaysia.
- Proceeds from new converting notes will support ongoing initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Holista Colltech Limited (HCT) ORDINARY FULLY PAID |
Consumer Staple |
$12 |
Proposed issue of securities - HCT
|
28 Feb 2025 9:53AM |
$0.030 |
$0.043 |
risen by
43.33%
|
|
| Altech Batteries Limited (ATC) ORDINARY FULLY PAID |
Materials |
$78 |
Acquisition of Additional Investments CERENERGY & Silumina
|
28 Feb 2025 9:53AM |
$0.045 |
$0.039 |
fallen by
13.33%
|
|
ATC - Price-sensitive ASX Announcement
Full Release
Key Points
- Altech to acquire additional 18.75% stake in CERENERGY® Project and additional 25% stake in Silumina AnodesTM Project.
- Post-acquisition, Altech will hold 100% ownership of the Silumina AnodesTM Project and 75% of the CERENERGY® Project.
- The transaction includes the issuance of approximately 532 million shares to AAM.
- The acquisitions are valued at approximately A$23.3 million.
- AAM will remain aligned with Altech's success through its 21% equity stake post-acquisition.
- The transaction is subject to shareholder approvals and necessary regulatory conditions.
- The acquisition aims to improve operational efficiency and consolidate project ownership.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Biotron Limited (BIT) ORDINARY FULLY PAID |
Health Care |
$4 |
Cancel - Proposed issue of securities - BIT
|
28 Feb 2025 9:53AM |
$0.009 |
$0.003 |
fallen by
66.67%
|
|
| Kina Securities Limited (KSL) ORDINARY FULLY PAID |
Financials |
$315 |
FY24 Results ASX Announcement
|
28 Feb 2025 9:53AM |
$1.170 |
$1.090 |
fallen by
6.84%
|
|
KSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Kina Securities Limited reported FY24 NPAT growth of 7% to PGK111.9 million.
- Net interest income increased by 15% year-on-year.
- Loan book grew by 13% year-on-year.
- Non-interest income grew by 33%, driven by FX income and digital channels.
- Total operating costs increased by 31% year-on-year.
- Final dividend declared at AUD 6.0 cents per share for 2H24.
- Cost to income ratio was 58.6% for the year.
- Capital adequacy maintained at 18.4%, supporting growth.
- KSL aims for further earnings growth in 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$577 |
Application for quotation of securities - BRN
|
28 Feb 2025 9:53AM |
$0.258 |
$0.285 |
risen by
10.68%
|
|
| Hudson Investment Group Limited (HGL) ORDINARY FULLY PAID |
Real Estate |
$10 |
Appendix 4E
|
28 Feb 2025 9:52AM |
$0.175 |
$0.175 |
fallen by
0%
|
|
HGL - Price-sensitive ASX Announcement
Full Release
Key Points
- Consolidated net loss after tax was $1.37 million for the year ended December 31, 2024.
- Revenue from ordinary activities rose by 1.2% to $1.498 million.
- Company does not recommend any dividends for the year.
- Engaged Knight Frank Central Coast for expressions of interest on property sales.
- Focus on optimizing current property portfolio for future growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Parkd Ltd (PKD) ORDINARY FULLY PAID |
Industrials |
$3 |
Appendix 4D and Interim Financial Report
|
28 Feb 2025 9:52AM |
$0.050 |
$0.029 |
fallen by
42%
|
|
PKD - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 508% to $6,179,314.
- Loss for the period was $82,252, down from $119,778.
- Key projects included Audi Centre Myaree and John Hughes Forward Street car park.
- Licensing agreement signed with Fielders for PARKD's intellectual property.
- Net operating cash inflow improved to $175,244.
- Total cash and cash equivalents were $761,623 as of December 31, 2024.
- Directors believe PARKD can continue as a going concern.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 |
Health Care |
$123 |
ASX waiver from requirement to lodge an Appendix 4E
|
28 Feb 2025 9:51AM |
$11.200 |
$7.980 |
fallen by
28.75%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
